Candel Therapeutics Inc (CADL)
Healthcare
Biotechnology
10.00 $
+1.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Candel Therapeutics Inc (CADL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.5% of the shares are freely tradable; institutional investors hold 59.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
59.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
15.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
77.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
24.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
73Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 15.00 | 10,987,017 | +33.4 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 8.76 | 6,422,018 | +0.0 | 03/31/2026 |
| BlackRock Inc | 4.24 | 3,109,042 | +8.6 | 03/31/2026 |
| Saturn V Capital Management LLC | 3.95 | 2,896,588 | +0.0 | 03/31/2026 |
| Portolan Capital Management, LLC | 3.95 | 2,894,325 | +70.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.36 | 2,462,757 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 3.15 | 2,305,060 | +14.8 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 6.64 | 4,864,753 | -17.7 | 04/30/2026 |
| Fidelity Growth Compy Commingled Pl S | 3.36 | 2,463,051 | +4.5 | 04/30/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.69 | 1,968,034 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.